scholarly journals Proteomics in Psoriasis

2019 ◽  
Vol 20 (5) ◽  
pp. 1141 ◽  
Author(s):  
Leena Chularojanamontri ◽  
Norramon Charoenpipatsin ◽  
Narumol Silpa-Archa ◽  
Chanisada Wongpraparut ◽  
Visith Thongboonkerd
Keyword(s):  
Biomarker Discovery ◽  
Skin Lesions ◽  
Psoriatic Skin ◽  
Drug Induced ◽  
Systematic Analysis ◽  
Therapeutic Outcomes ◽  
Genetic And Environmental Factors ◽  
Monitoring Treatment ◽  
Adaptive Immune Systems ◽  
Abnormal Cell Proliferation

Psoriasis has been thought to be driven primarily by innate and adaptive immune systems that can be modified by genetic and environmental factors. Complex interplay between inflammatory cytokines and T-cells, especially Th1 and Th17 cells, leads to abnormal cell proliferation and psoriatic skin lesions. Nevertheless, such mechanisms do not entirely represent the pathogenesis of psoriasis. Moreover, earlier and better biomarkers in diagnostics, prognostics, and monitoring therapeutic outcomes of psoriasis are still needed. During the last two decades, proteomics (a systematic analysis of proteins for their identities, quantities, and functions) has been widely employed to psoriatic research. This review summarizes and discusses all of the previous studies that applied various modalities of proteomics technologies to psoriatic skin disease. The data obtained from such studies have led to (i) novel mechanisms and new hypotheses of the disease pathogenesis; (ii) biomarker discovery for diagnostics and prognostics; and (iii) proteome profiling for monitoring treatment efficacy and drug-induced toxicities.

scholarly journals Multiple Sclerosis Biomarker Discoveries by Proteomics and Metabolomics Approaches

2021 ◽  
Vol 16 ◽  
pp. 117727192110133
Author(s):  
Ameneh Jafari ◽  
Amirhesam Babajani ◽  
Mostafa Rezaei-Tavirani
Keyword(s):  
Multiple Sclerosis ◽  
Complex Disease ◽  
Biomarker Discovery ◽  
Response To Treatment ◽  
Inflammatory Disorder ◽  
Protein Marker ◽  
Complex Disorders ◽  
New Information ◽  
The Central Nervous System ◽  
Monitoring Treatment

Multiple sclerosis (MS) is an autoimmune inflammatory disorder of the central nervous system (CNS) resulting in demyelination and axonal loss in the brain and spinal cord. The precise pathogenesis and etiology of this complex disease are still a mystery. Despite many studies that have been aimed to identify biomarkers, no protein marker has yet been approved for MS. There is urgently needed for biomarkers, which could clarify pathology, monitor disease progression, response to treatment, and prognosis in MS. Proteomics and metabolomics analysis are powerful tools to identify putative and novel candidate biomarkers. Different human compartments analysis using proteomics, metabolomics, and bioinformatics approaches has generated new information for further clarification of MS pathology, elucidating the mechanisms of the disease, finding new targets, and monitoring treatment response. Overall, omics approaches can develop different therapeutic and diagnostic aspects of complex disorders such as multiple sclerosis, from biomarker discovery to personalized medicine.

Activated and cycling lymphocytes in benign dermal lymphocytic infiltrates including psoriatic skin lesions

1985 ◽  
Vol 278 (2) ◽  
pp. 92-96 ◽  
Author(s):  
G. Lange Wantzin ◽  
J. K. Larsen ◽  
I. J. Christensen ◽  
E. Ralfkiaer ◽  
M. Tjalve ◽  
...  
Keyword(s):  
Skin Lesions ◽  
Psoriatic Skin ◽  
Lymphocytic Infiltrates

Psoriatic skin lesions induced by abatacept: Case report and review of the published work

2016 ◽  
Vol 44 (7) ◽  
pp. 845-846 ◽  
Author(s):  
Ikuko Ueda-Hayakawa ◽  
Chuyen Nguyen Thi Hong ◽  
Yoko Ueki ◽  
Naotomo Kambe ◽  
Hiroyuki Okamoto
Keyword(s):  
Case Report ◽  
Skin Lesions ◽  
Psoriatic Skin

Ankylosing spondylitis, other spondyloarthritides, and related conditions

2010 ◽  
pp. 3603-3616 ◽  
Author(s):  
J. Braun ◽  
J. Sieper
Keyword(s):  
Rheumatoid Arthritis ◽  
Back Pain ◽  
Ankylosing Spondylitis ◽  
Gastrointestinal Tract ◽  
Rheumatic Diseases ◽  
Skin Lesions ◽  
Inflammatory Back Pain ◽  
Psoriatic Skin ◽  
Inflammatory Rheumatic Diseases ◽  
History Of

The spondyloarthritides are a group of inflammatory rheumatic diseases with predominant involvement of axial and peripheral joints and entheses, together with other characteristic clinical features, including inflammatory back pain, sacroiliitis, peripheral arthritis (mainly in the legs), enthesitis, dactylitis, preceding infection of the urogenital/gastrointestinal tract, psoriatic skin lesions, Crohn-like gut lesions, anterior uveitis, and a family history of Spondyloarthritis. They are the second most frequent inflammatory rheumatic diseases after rheumatoid arthritis....

scholarly journals Changes in Proteome of Fibroblasts Isolated from Psoriatic Skin Lesions

2020 ◽  
Vol 21 (15) ◽  
pp. 5363
Author(s):  
Agnieszka Gęgotek ◽  
Pedro Domingues ◽  
Adam Wroński ◽  
Elżbieta Skrzydlewska
Keyword(s):  
Signal Transduction ◽  
Skin Lesions ◽  
Dermal Fibroblasts ◽  
Metabolic Effects ◽  
Psoriatic Skin ◽  
Proteomic Profile ◽  
Intercellular Signaling ◽  
Antioxidant Proteins ◽  
Skin Epidermis ◽  
Proinflammatory Factors

The dermal fibroblasts are in constant contact with the cells of the immune system and skin epidermis. Therefore, they are essential for the development of lesions in psoriasis. The aim of this study was to assess the changes in the proteomic profile of fibroblasts in the dermis of psoriasis patients, and to discuss the most significant changes and their potential consequences. The proteomic results indicate that fibroblast dysfunction arises from the upregulation of proinflammatory factors and antioxidant proteins, as well as those involved in signal transduction and participating in proteolytic processes. Moreover, downregulated proteins in psoriatic fibroblasts are mainly responsible for the transcription/translation processes, glycolysis/ adenosine triphosphate synthesis and structural molecules. These changes can directly affect intercellular signaling and promote the hyperproliferation of epidermal cells. A better understanding of the metabolic effects of the proteomic changes observed could guide the development of new pharmacotherapies for psoriasis.

scholarly journals Effects of Systemic Interleukin-10 Therapy on Psoriatic Skin Lesions: Histologic, Immunohistologic, and Molecular Biology Findings

2001 ◽  
Vol 116 (5) ◽  
pp. 721-727 ◽  
Author(s):  
Khusru Asadullah ◽  
Markus Friedrich ◽  
Sandra Hanneken ◽  
Christoph Rohrbach ◽  
Heike Audring ◽  
...  
Keyword(s):  
Molecular Biology ◽  
Skin Lesions ◽  
Interleukin 10 ◽  
Psoriatic Skin

scholarly journals Asymmetric stem-cell division ensures sustained keratinocyte hyperproliferation in psoriatic skin lesions

2015 ◽  
Vol 37 (2) ◽  
pp. 359-368 ◽  
Author(s):  
HAI-YAN JIA ◽  
YING SHI ◽  
LONG-FEI LUO ◽  
GUAN JIANG ◽  
QIONG ZHOU ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cell Division ◽  
Skin Lesions ◽  
Psoriatic Skin ◽  
Stem Cell Division

Association between Vasculitides and Myelodysplastic Syndrome (MDS): A Report on 21 Cases.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4714-4714 ◽  
Author(s):  
O. Fain ◽  
M. Hamidou ◽  
P. Cacoub ◽  
B. Godeau ◽  
J. Stirnemann ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Renal Involvement ◽  
Relapsing Polychondritis ◽  
Hematologic Malignancies ◽  
Skin Lesions ◽  
Drug Induced ◽  
Steroid Dependence ◽  
Granulomatous Vasculitis ◽  
Cancer Remission ◽  
Median Interval

Abstract Vasculitis rarely complicates solid tumors but is more common in hematologic malignancies, particularly MDS,. We report characteristics and outcome of 21 patients with both MDS and vasculitis. Patients: We retrospectively collected data of patients with at least 1 malignancy (including MDS) and vasculitis diagnosed between 1992 and 2002 in 6 French centers. Vasculitides occurring during cancer remission were excluded, as were giant-cell arteritis, relapsing polychondritis (a well known association with MDS), cryoglobulinemia, infection- or drug-induced vasculitis. Results: 60 patients, with median follow-up of 45 months were analyzed. Vasculitides diagnosed were: cutaneous leukocytoclastic (LV,45%), polyarteritis nodosa (PAN,36.7%), Wegener’s granulomatosis (WG,6.7%), microscopic polyangiitis (MPA,5%), Henoch-Schonlein purpura( HSP,5%). Cancers were hematological (66.7%) (including 21 MDS (35%) and (23%) lymphoid malignancies) and solid tumors (41.7%). Five patients had 2 cancers. 21 patients had vasculitis associated with MDS (median age 66 yr; M/F ratio 4.25). FAB classification was: RAEB (n=11), RA (n=3) and CMML (n=7). Vasculitides were LV (n=9), PAN (n=9), MPA(n=1), WG (n=1), cutaneous granulomatous vasculitis (n=1).CMML were only associated with necrotizing vasculitis ( 6PAN, 1WG). Vasculitis and MDS were diagnosed simultaneously in 12(57%) cases, vasculitis was diagnosed after MDS in 8 (38%) cases (median interval: 11 months, range 1–45) and 6 months before MDS in 1 case.9 MDS progressed to AML. Vasculitides developed before or at the time of leukemic progression in 6 of them (median interval 3 months, range 0–12). Main vasculitis symptoms were: fever (47%), skin lesions(81%), arthralgias (62%), peripheral neuropathy (14%), renal involvement (43%)[microaneurysms 29%, renal failure 9.5%, glomerulonephritis 9.5%], inflammatory syndrome (81%), ANCA (20%). Vasculitis therapy was steroids (90%) +/− immune suppressors (33%). MDS treatment was: AraC( n:2), VP16 (n:3), hydroxyurea (n:2),allogeneic BMT (n:2), symptomatic (n:12). Vasculitis was cured in 10 (47%) cases. 17 (81%) patients died; only 1 death was linked to vasculitis. Regardless of the type, vasculitides associated with MDS had significantly more frequent renal involvement (p=0.02),steroid dependence (p=0.04), and less recovery (p=0.04) than vasculitides without MDS Conclusion: Vasculitides associated to MDS appear to have distinctive features and more severe evolution.In addition, occurrence of vasculitides during the course of MDS may be associated with a high risk of rapid leukemic progression.

Sign in / Sign up

Export Citation Format

Share Document